Commissioner Hamburg on Global Drug Regulation and FDA Challenges


Applied Clinical Trials

Jill Wechsler provides a special report of a briefing with FDA's new commissioner Margaret Hamburg.

The new commissioner of the Food and Drug Administration is mapping plans for turning around an agency that has been demoralized, buffeted about in the press and has lost some of the trust of the American people. “Our mission is to protect the health of the people, using the best available science, in as transparent ways as possible, across all domains,” Margaret Hamburg told Applied Clinical Trials in a media briefing last week, part of her campaign to enhance communication about FDA policies and goals.

A lead initiative is to define FDA’s “global footprint” for dealing with food safety and drug and medical product development on an international basis. Establishing overseas offices is just one aspect of developing a more comprehensive and strategic approach to addressing global health issues, Hamburg explained. These hubs provide more on-the-ground understanding of local developments and will permit “more nimbleness in a crisis,” she pointed out. But FDA also needs to develop partnerships with sister regulatory agencies to promote harmonization and to provide more assistance and capacity-building in countries with less developed regulatory frameworks.

Tackling tobacco
A high priority for FDA is to develop a framework for regulating tobacco products. Hamburg feels strongly that FDA, as a science-based public health regulatory agency, is the appropriate organization to address the “really important public health problems” raised by tobacco use. The agency is still developing staffing plans and the roll-out for a new tobacco center, but Hamburg believes that the new legislation provides the needed tools and authorities and does not “really overload the plate” at FDA. She does not expect to take resources from other areas to support tobacco regulation or that broader organizational changes will be needed.

Despite the heightened focus on food safety and tobacco regulation, the drug and medical product area is core to FDA’s mission, Hamburg emphasized, adding that “I do not see us stepping away from that important component.” She regards industry as “absolutely key partners in what we do” and aims “to get more involved in issues of innovation and in providing swift reviews of new products.” This a good time, she feels, to take a new look at the Critical Path Initiative and at how FDA can leverage emerging science and technology to strengthen new product development and review, as well as postmarket surveillance and product communication.

In the marketing and promotion area, Hamburg says she “cares deeply about making sure consumers get access to appropriate and adequate information about the choices they need to make.” She is concerned that in “this very complicated media world” with an increasing range of blogs, Internet sites, 24-hour cable TV and an array of media outlets, “it is very easy for inaccurate information to get out there. We have a real responsibility to make sure that where we have authority and opportunity, we provide the clearest and most accessible public health message possible.” Hamburg says she wants to work more with drug companies and advertising firms to ensure that any information on medical products is accurate and reliable and reflects available scientific data.

Hamburg also anticipates a closer working relationship with the Centers for Medicare and Medicaid Services (CMS) to help move medical products “out of the review process and into the market place.” Early discussions can help CMS understand what new products will emerge, which may enable them to streamline their own procedures for review and reimbursement, she explains.

The commissioner recognizes the importance of having the resources to attract and retain the expertise needed to accomplish these many goals. And she hopes that her leadership will be marked by a “strong and clear emphasis on science-based decision making.” If there’s a question about the safety or efficacy of a drug on the market, though, “I will not have any hesitancy about examining it closely” she warns.

Setting up a new tobacco center will take some juggling, Hamburg acknowledges, but it is a high priority. How FDA takes on these new responsibilities “will be looked at as a measure of FDA’s leadership,” she says. “FDA needs to make significant strides forward in order to accomplish its mission in a global world.”

Related Content
© 2024 MJH Life Sciences

All rights reserved.